To further validate these findings using clinical data, we retrospectively analyzed microarray data from patients with luminal A subtype breast cancer who received long-term (16 weeks, n = 23) or short-term (4 weeks, n = 26) CDK4/6i therapy (49). Here, CDK4 is linked to breast carcinoma.